Abstract
Gualou Xiebai is a foundational Traditional Chinese Medicine (TCM) prescription originally documented in the Synopsis of the Golden Chamber for the treatment of angina pectoris. This review synthesizes current theoretical research and clinical applications of Gualou Xiebai, bridging 1,800-year-old clinical wisdom with modern pharmacological evidence to promote its integrated use in treating coronary heart disease (CHD).
Introduction
Coronary heart disease (CHD) remains a primary driver of global mortality, characterized by myocardial ischemia and hypoxia resulting from coronary artery narrowing. While modern Western medicine provides critical acute interventions such as statins and stent placements, there is an increasing demand for holistic, multi-target therapies for long-term management. Gualou Xiebai offers a unique therapeutic framework that addresses the complex interplay of physiological imbalances underlying CHD.
Theoretical Foundations: The "Too High/Too Low" Framework
In classical TCM theory, angina pectoris is often attributed to a state of "too high" (excess of pathogenic factors like phlegm) and "too low" (deficiency of heart Yang). Gualou Xiebai functions by warming the "Yang" to facilitate fluid movement while simultaneously clearing the "turbid sputum" that obstructs the chest.
A central insight of this review is the synergy between phlegm and blood stasis. These two factors are not independent; phlegm accumulation hinders blood circulation, and blood stasis conversely leads to fluid retention. By addressing both simultaneously, Gualou Xiebai targets the root causes of coronary obstruction more effectively than therapies focusing on a single pathway.
Pharmacological Mechanisms and Herb Components
Modern biochemical research has identified several multi-target mechanisms through which Gualou Xiebai exerts its cardioprotective effects, including vasodilation, anti-thrombotic activity, and protection against reperfusion injury.
Core Components:
- Trichosanthes kirilowii (Gualou): This herb is proven to expand coronary arteries and protect the ischemic myocardium from damage.
- Allii Macrostemonis Bulbus (Xiebai): Clinical studies indicate its efficacy in reducing blood lipids and preventing the progression of atherosclerosis.
- Salvia miltiorrhiza (Danshen): Often added to the base formula, Danshen is noted for its ability to scavenge free radicals and regulate calcium metabolism within heart cells.
Clinical Synthesis and Data Insights
The review draws upon large-scale data-mining efforts to validate clinical efficacy. Analysis of 269 articles containing Gualou Xiebai prescriptions and a collection of 400 prescriptions for chest pain from TCM masters highlights the consistency of its application. Meta-analyses suggest that variations such as the Gualou Xiebai Banxia Decoction significantly reduce the frequency of angina attacks and improve vascular endothelial function.
Limitations and Future Directions
Despite its clinical promise, the integration of Gualou Xiebai into mainstream practice faces challenges. The lack of standardization in decoction potency and the absence of a seamless "complete treatment system" combining Western emergency care with TCM’s long-term prevention are notable hurdles.
Future efforts should focus on establishing an integrated Chinese-Western medical system. Further research into the "multi-channel" pharmacological nature of these herbs will be essential to refining evidence-based clinical applications and decreasing CHD mortality rates.
Summary updated